Light Therapy for Obsessive-compulsive Disorder (OCD)

Obsessive-Compulsive Disorder Clinical Trial

Official title:

A Circadian Medicine Light-based Intervention for Obsessive-compulsive Disorder (OCD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05391503
• Other study ID #: 270-FP-22
• Status: Recruiting
• Phase: N/A
• Start date: September 23, 2022
• Est. completion date: August 2024

Study information

• Verified date: October 2023
• Source: University of Colorado, Boulder
• Contact: Rebecca C Cox, PhD
• Phone: 303-735-1923
• Email: sleep.study[@]colorado.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the effect of a light-based circadian treatment on OCD symptoms in adults with OCD and late bedtimes. This study will have important implications for understanding the role of circadian rhythms in the etiology and treatment of OCD.

Description:

Prior to the start of this study, there are screening procedures to ensure participants meet the criteria for the study. At the first consent screening appointment, participants will learn more about the study and answer questionnaires. All of the results of the screening procedures are confidential and will only be used by the study staff to determine eligibility for the study.

This study is 5 weeks long and involves 4 in-person lab visits at the Sleep and Chronobiology Lab. Participants will be randomly assigned to either an active or placebo light therapy treatment condition. Visit 1 will involve additional screening to determine eligibility, including questionnaires and interviews. If eligible, participants will then track their sleep for 2 weeks at home with a wrist-worn activity monitor and a sleep diary. Visit 2 will take place in the lab from 5:30pm until 1 hour after participants typical bedtime. The investigators will ask participants to provide saliva samples hourly to measure melatonin and complete questionnaires. The investigators will provide treatment instructions at this visit. Investigators will then ask participants to engage in the treatment at home for 3 weeks. Investigators will schedule 1 in-person visit (Visit 3) and 1 phone call to assess adherence to the treatment during these 3 weeks. Visit 4 will take place in the lab after the treatment is finished. Visit 4 will last from 5:30pm until 1.5 hours after participants typical bedtime and will involve hourly saliva samples to measure melatonin, questionnaires, and interviews.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Primary OCD diagnosis (according to the Diagnostic and Statistical Manual of Mental Disorders 5)

• Bedtime 0100 or later

• Age 18-35

• English speaking

Exclusion Criteria:

• Subjects must not be currently participating in another research study that would influence their participation in our study.

• Past 6-month substance use disorder

• Lifetime psychosis or bipolar disorder

• Current sleep disorder (DSWPD and insomnia excepted)

• Significant, active suicidal ideation or behaviors in the past 6 months

• Intellectual disability

• Engaged in evidence-based psychotherapy for OCD

• History of light therapy or cognitive behavior therapy for insomnia

• Night shift work or travel outside of Mountain Standard Time in the past month

• Pregnant, trying to become pregnant, or breastfeeding

• Change in psychotropic medication in the past month

• Prescribed or over the counter sleep medication use in the past month

• Beta-block or monoamine oxidase inhibitor use in the past month

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder

Intervention

Behavioral:
• Light therapy
Morning bright light for 60 minutes after awakening
• Placebo light therapy
Placebo morning bright light for 60 minutes after awakening

Locations

Country	Name	City	State
United States	Sleep and Chronobiology Laboratory	Boulder	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Boulder

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Circadian phase	Circadian phase assessed by dim light melatonin onset (DLMO)	3 weeks
Primary	Obsessive-Compulsive Inventory-Revised score	Self-reported OCD symptoms. Minimum score=0, maximum score=74. Higher scores indicate worse outcome	3 weeks
Secondary	Yale-Brown Obsessive-Compulsive Scale score	Interviewer-assessed OCD symptoms. Minimum score=0, maximum score=40. Higher scores indicate worse outcome	5 weeks